Skip to content
Clinical Trials – home
Helse Bergen HF
Sponsor

Helse Bergen HF

Norway Haukelandsveien 22, 5021 Bergen, Norway

About the sponsor

Clinical research includes acute myeloid leukemia, high-risk myelodysplastic syndrome, breast cancer, pancreatic cancer, and recurrent grade IV glioma. The funded studies also address treatment response, resistance, and survival in aggressive cancer settings.

  • Acute myeloid leukemia
  • Breast cancer
  • Pancreatic cancer
  • Recurrent grade IV glioma

Research activity spans both solid tumours and blood cancers, with interest in personalised treatment strategies and disease control in difficult-to-treat malignancies.

About Specializations

Helse Bergen HF runs clinical trials in conditions such as Multiple sclerosis, Chronic fatigue syndrome, Cluster headache, Breast cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

26 clinical trials

Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Tenofovir Alafenamide
  • Sponsor:Helse Bergen HF

Crohn's disease

Recruiting
Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Macrogol 3350
  • Sponsor:Helse Bergen HF
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Daratumumab
  • Sponsor:Helse Bergen HF
Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Helse Bergen HF
Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Metyrapone
  • Sponsor:Helse Bergen HF
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Dexamfetamine Sulfate
  • Sponsor:Helse Bergen HF
Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Helse Bergen HF
Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Helse Bergen HF
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Hydroxycarbamide
  • Sponsor:Helse Bergen HF
Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Helse Bergen HF
Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Nitrous Oxide
  • Sponsor:Helse Bergen HF
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Helse Bergen HF

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).